The overall goal of the Clinical Core is to provide University of Kansas (KU) Alzheimer's Disease Core Center (ADCC) investigators with access to a well-characterized cohort of research participants with and without dementia. The Clinical Core will continue to emphasize recruiting nondemented individuals and those in the earliest symptomatic stages of AD, including mild cognitive impairment (MCI). This overall goal will be met by the following specific aims:
Aim 1. Maintain an active cohort of nondemented, mild cognitive impairment (MCI) and AD subjects to support cross-sectional and longitudinal studies.
Aim 2. Support and encourage collaborative interdisciplinary studies on AD and aging by providing data, biological specimens, and clinical research infrastructure, expertise and support to approved investigators and national data sharing initiatives (i.e., NACC). The initiation of the Clinical Core in 2004 (previously known as the Alzheimer and Memory Program) has stimulated the growth of AD and aging research at KU. In six years, the program has significantly broadened the base of AD investigators by stimulating collaborative studies, providing a training environment for the next generation of AD investigators, and by attracting new faculty to the campus. The Clinical Core has developed essential infrastructure and participant recruitment capabilities that directly supports the research efforts of faculty members in the Schools of Medicine, Allied Health, and Nursing. The research and training foundation of the Clinical Core will provide KU investigators with the infrastructure to build on this history and pursue the novel role of metabolic dysfunction in neurodegeneration and aging.
With the aging population, age-related disorders such as dementia are rising in prevalence at an unprecedented rate. Prompting and supporting clinical and translational research into neurodegenerative disorders may lead to important prevention and treatment strategies.
|Wilkins, Heather M; Swerdlow, Russell H (2016) Relationships Between Mitochondria and Neuroinflammation: Implications for Alzheimer's Disease. Curr Top Med Chem 16:849-57|
|LoBue, Christian; Denney, David; Hynan, Linda S et al. (2016) Self-Reported Traumatic Brain Injury and Mild Cognitive Impairment: Increased Risk and Earlier Age of Diagnosis. J Alzheimers Dis 51:727-36|
|Dardis, A; Zampieri, S; Canterini, S et al. (2016) Altered localization and functionality of TAR DNA Binding Protein 43 (TDP-43) in niemann- pick disease type C. Acta Neuropathol Commun 4:52|
|Lai, Dongbing; Xu, Huiping; Koller, Daniel et al. (2016) A MULTIVARIATE FINITE MIXTURE LATENT TRAJECTORY MODEL WITH APPLICATION TO DEMENTIA STUDIES. J Appl Stat 43:2503-2523|
|Ahmed, Ali Bani; Cirstea, Carmen M (2016) Positive Effect of Impairment-Oriented Training on N-Acetylaspartate Levels of Ipsilesional Motor Cortex in Subcortical Stroke: A Case Study. Int J Phys Med Rehabil 4:|
|Day, Gregory S; Musiek, Erik S; Roe, Catherine M et al. (2016) Phenotypic Similarities Between Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease: A Single-Family Case-Control Study. JAMA Neurol 73:1125-32|
|Ronquillo, Jay Geronimo; Baer, Merritt Rachel; Lester, William T (2016) Sex-specific patterns and differences in dementia and Alzheimer's disease using informatics approaches. J Women Aging 28:403-11|
|Ringman, John M; Monsell, Sarah; Ng, Denise W et al. (2016) Neuropathology of Autosomal Dominant Alzheimer Disease in the National Alzheimer Coordinating Center Database. J Neuropathol Exp Neurol 75:284-90|
|Wilkins, Heather M; Koppel, Scott; Carl, Steven M et al. (2016) Oxaloacetate enhances neuronal cell bioenergetic fluxes and infrastructure. J Neurochem 137:76-87|
|Besser, Lilah M; Alosco, Michael L; Ramirez Gomez, Liliana et al. (2016) Late-Life Vascular Risk Factors and Alzheimer Disease Neuropathology in Individuals with Normal Cognition. J Neuropathol Exp Neurol 75:955-962|
Showing the most recent 10 out of 173 publications